slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 32,041-32,070
Pages 1,418
Rows per page 30
Beat
32,041-32,070 of 42,534
07
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
Scientific diagram illustrating the mechanism of antigen presentation and T cell maturation.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a biological diagram to explain the 'problem' of immune evasion in cancer therapy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
11
The diagram uses a funnel-like or layered process flow to map biological mechanisms to specific immune outcomes.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
12
The slide uses a process flow diagram to illustrate the 8-step manufacturing timeline.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a red border to highlight the RENB-DC11 row as the superior alternative.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The diagram illustrates a complex supply chain process involving biopsy, manufacturing, and clinical administration.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a combination of a process diagram and dot plots to validate the model's performance.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
The slide presents two bar charts (weight and volume) and a grid of tumor photographs as visual proof of concept.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
Includes visual evidence of tumor size alongside quantitative bar charts with statistical significance markers.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The table shows 0/3 incidence of metastasis/ascites in the RENB-DC11 group compared to high incidence in control groups.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide presents two bar charts comparing control, tumor, tumor+mock, and tumor+TD groups under different treatment conditions (IL2 vs aCD16).Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
N=2-3 sample size indicated at bottom left.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The slide demonstrates efficacy of RENB-DC11 in stimulating immune response (IFNg production) in a tumor model.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses immunohistochemistry (brown staining) to visualize CD4+ T-cells, quantified in the bar chart.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
The slide uses immunohistochemistry images and a corresponding bar chart to demonstrate efficacy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
This is a standard TPP (Target Product Profile) table used in biotech/pharma pitch decks.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
The slide outlines a clinical development plan with specific milestones for 2025 and 2026, focusing on safety and efficacy cohorts.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
26
The slide contrasts the traditional CRO outsourcing model with a direct management model to justify cost efficiency.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
Standard corporate legal disclosure slide.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a series of iterative loop icons to represent the learning process.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
22
The scatter plot highlights a specific cluster of compounds (labeled 1 and 2) that were selected by the active learning model despite being outside the typical high-potency/high-score Pareto frontier.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
23
The slide highlights technical infrastructure and R&D capabilities.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
24
The slide uses a process flow diagram to connect target criteria to computational optimization and final project telemetry.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
25
The diagram uses a hub-and-spoke style flow to show data integration, generative design, and iterative refinement.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
26
The slide features a 3D molecular model and a set of circular gauges representing various drug discovery metrics (potency, stability, toxicity, etc.).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
27
The slide highlights technical capabilities in computational chemistry/drug discovery.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
28
The slide uses a pyramid diagram to show a hierarchical process of drug discovery automation.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit